INCYIncyte CorporationFinished
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 59 (final count)
- Started
- Dec 20, 2016
- Main results expected
- Dec 24, 2025
- Fully finished
- Dec 24, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Frequency, severity, and duration of adverse events (AEs)
Measured over: From screening through 30-35 days after end of treatment, approximately 2 years.
Phase 1: Number of subjects with dose-limiting toxicities (DLTs)
Measured over: Day 1 through Day 28
Phase 2: Objective response rate (ORR) based on RECIST v1.1
Measured over: Screening and 8-week intervals throughout the study, approximately 2 years.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02917993 · record last updated 2026-02-09 · checked 2026-11-09 15:47 UTC